SIM
KRYS icon

Sandia Investment Management’s Krystal Biotech KRYS Stock Holding History

Sandia Investment Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,194
Closed -$275K – 269
2022
Q2 		$275K Sell
4,194
-806
-16% -$50.1K 0.04% 190
2022
Q1 		$333K Hold
5,000
– – 0.05% 186
2021
Q4 		$350K Buy
+5,000
New +$291K 0.06% 150

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Sandia Investment Management's KRYS Position: Q3 2022 in Review

Sandia Investment Management sold out of Krystal Biotech (KRYS) in Q3 2022, closing a stake of 4,194 shares — an estimated $275K sold.

Sandia Investment Management first reported a position in KRYS in Q4 2021 and held it in 3 quarters. The position peaked at $350K in Q4 2021. 148 funds tracked by Wall St. Rank hold KRYS as of Q3 2022.

  • Sandia Investment Management reported no remaining Krystal Biotech position as of Q3 2022 after selling out during the quarter.
  • Sandia Investment Management sold 4,194 Krystal Biotech shares in Q3 2022, an estimated $275K.
  • Sandia Investment Management first reported a position in Krystal Biotech in Q4 2021 and held it in 3 quarters.
  • Sandia Investment Management's Krystal Biotech position peaked at $350K in Q4 2021.
  • 148 funds tracked by Wall St. Rank held Krystal Biotech as of Q3 2022.

Based on Sandia Investment Management's 13F filing for Q3 2022, filed 15 Nov 2022.